The first cross-border acquisition order of the year has arrived
Posted: Wed Feb 12, 2025 10:32 am
With RMB 800 million invested in growth hormone, Shengxiang Biopharma acquires Zhongshan Haiji
According to the latest public announcement of Shengxiang Bio, the company plans to acquire 100% equity of Zhongshan Weiming Haiji Biotechnology Co., Ltd. (referred to as "Zhongshan Haiji") for RMB 807.5 million in cash. After the transaction is completed, Zhongshan Haiji will become a wholly-owned subsidiary of the company.
The company stated that the acquisition was intended to actively implement the country's call for children's health management and promote long-term balanced population development. At the same time, it would utilize the company's business advantages in in vitro diagnostics and Zhongshan Haiji's business advantages in growth hormone to promote the company's comprehensive strategic layout of "integrated diagnosis and treatment" and enhance the company's profitability.
However, competition in the growth hormone market is job seekers data becoming increasingly fierce. Some institutions predict that the global market size will be approximately US$3.4 billion in 2022, with a compound annual growth rate of approximately 8.1%, and is expected to reach a market size of US$7.3 billion by 2032. The Chinese market is also showing a rapid growth trend. In 2021, the scale of China's growth hormone market exceeded 10 billion yuan, and exceeded 12 billion yuan in 2022.
As parents pay more attention to their children's dwarfism and medical technology continues to advance, it is expected that the penetration rate of growth hormone will increase to about 10% in the next 5-10 years, which will bring huge market growth space for the growth hormone industry.
This time, Shengxiang Bio has set its sights directly on the field of biologics in the pharmaceutical field.
According to the announcement, Shengxiang Bio plans to acquire 100% of the equity of Zhongshan Weiming Haiji Biotechnology Co., Ltd. for RMB 807.5 million in cash.
Zhongshan Weiming Haiji Biopharmaceutical Co., Ltd. was established in 2004 and is located in the National Health Base in Torch District, Zhongshan City. It is a genetic engineering biopharmaceutical company with independent intellectual property rights.
According to the latest public announcement of Shengxiang Bio, the company plans to acquire 100% equity of Zhongshan Weiming Haiji Biotechnology Co., Ltd. (referred to as "Zhongshan Haiji") for RMB 807.5 million in cash. After the transaction is completed, Zhongshan Haiji will become a wholly-owned subsidiary of the company.
The company stated that the acquisition was intended to actively implement the country's call for children's health management and promote long-term balanced population development. At the same time, it would utilize the company's business advantages in in vitro diagnostics and Zhongshan Haiji's business advantages in growth hormone to promote the company's comprehensive strategic layout of "integrated diagnosis and treatment" and enhance the company's profitability.
However, competition in the growth hormone market is job seekers data becoming increasingly fierce. Some institutions predict that the global market size will be approximately US$3.4 billion in 2022, with a compound annual growth rate of approximately 8.1%, and is expected to reach a market size of US$7.3 billion by 2032. The Chinese market is also showing a rapid growth trend. In 2021, the scale of China's growth hormone market exceeded 10 billion yuan, and exceeded 12 billion yuan in 2022.
As parents pay more attention to their children's dwarfism and medical technology continues to advance, it is expected that the penetration rate of growth hormone will increase to about 10% in the next 5-10 years, which will bring huge market growth space for the growth hormone industry.
This time, Shengxiang Bio has set its sights directly on the field of biologics in the pharmaceutical field.
According to the announcement, Shengxiang Bio plans to acquire 100% of the equity of Zhongshan Weiming Haiji Biotechnology Co., Ltd. for RMB 807.5 million in cash.
Zhongshan Weiming Haiji Biopharmaceutical Co., Ltd. was established in 2004 and is located in the National Health Base in Torch District, Zhongshan City. It is a genetic engineering biopharmaceutical company with independent intellectual property rights.